1-((4-Fluorophenyl)carbamoyl)cyclopropanecarboxylic acid

We are 1-((4-Fluorophenyl)carbamoyl)cyclopropanecarboxylic acid CAS:849217-48-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1-((4-Fluorophenyl)carbamoyl)cyclopropanecarboxylic acid
CAS.NO:849217-48-7
Synonyms:1-[(4-fluorophenyl)carbamoyl]cyclopropane-1-carboxylic acid
Molecular Formula:C11H10FNO3
Molecular Weight:223.20000
 
Physical and Chemical Properties:
Density:1.521
Boiling point:475.2ºC
Flash point:217ºC
Index of Refraction:1.651
 
Specification:
Appearance:White crystalline powder
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Cabozantinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

1-((4-Fluorophenyl)carbamoyl)cyclopropanecarboxylic acid


Related News: As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.acetoína CAS:513-86-0 Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.S-2-benzotiazolil (Z) -2- (5-amino-1,2,4-tladlazol-3-il) -2-metoxilino tioacetato CAS:104797-47-9 Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.2- (2-metoxietoxi) -N- (oxometilideno) CAS:89020-61-1 API and raw material are often confused due to the similar usage of the two terms.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Related Products
Product Name
(5-formylfuran-2-yl)boronic acid View Details
N2-acetyl-L-lysine View Details
2-Methyl-4-[(2-methylbenzoyl)amino]benzoic acid View Details
6-Bromo-5-chloropyridin-2-amine manufacturer 1,4-Cyclohexanedimethanol manufacturer Allyl chloride manufacturer (2S)-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]propanoic acid manufacturer (2R,3R,4S,5R)-2-(6-amino-2-iodopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol manufacturer